Biocept
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Biocept generated cash of -$13,289,000, which is less than the previous year. Cash used in financing activities reached the amount of -$1,871,000 last year. Net change in cash is therefore -$15,967,000.
Cash Flow
| 2013 | -6.20M | -711 | 6.08M |
|---|---|---|---|
| 2014 | -14.60M | -394.92K | 20.29M |
| 2015 | -15.15M | -165.16K | 18.77M |
| 2016 | -15.69M | -451.40K | 11.93M |
| 2017 | -19.65M | -1.40M | 18.58M |
| 2018 | -22.35M | -145.25K | 23.77M |
| 2019 | -23.04M | -735.3K | 29.66M |
| 2020 | -19.78M | -866.81K | 25.72M |
| 2021 | 3.69M | -1.57M | 12.37M |
| 2022 | -13.28M | -807K | -1.87M |
BIOC Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 28.86M | 14.36M | 9.30M | 3.42M | 2.14M | 4.60M | 8.82M | 5.36M | 69.17K | 185.25K |
Operating activities | ||||||||||
Net income | -32.08M | -2.82M | -17.80M | -25.13M | -24.57M | -21.61M | -18.39M | -16.94M | -15.86M | -9.23M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.65M | 2.63M | 1.00M | 773.31K | 800.90K | 575.71K | 322.02K | 261.40K | 251.20K | 266.55K |
Stock-based compensation expense | 3.22M | 2.46M | 940.98K | 869.57K | 623.41K | 1.24M | 1.59M | 1.37M | 1.82M | 952.52K |
| Deferred income tax benefit | 3.22M | 2.46M | 940.98K | 869.57K | 623.41K | 1.24M | 1.59M | 1.37M | 1.82M | 952.52K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 11.63M | 358K | -10.61M | -1.95M | -380.89K | -1.06M | -94.76K | -23.6K | -1.4K | 9.68K |
Inventories | 1.89M | -828K | -1.40M | -194.92K | -50.02K | 100.87K | -168.11K | -126.10K | -82.12K | 38.46K |
Accounts payable | -5.86M | -411K | 4.46M | 14.83K | 601.87K | 349.93K | 332.73K | -51.79K | -981.86K | -175.28K |
Cash generated by operating activities | -13.28M | 3.69M | -19.78M | -23.04M | -22.35M | -19.65M | -15.69M | -15.15M | -14.60M | -6.20M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -807K | -1.57M | -866.81K | -735.3K | -145.25K | -1.40M | -482.06K | -165.16K | -394.92K | -711 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -807K | -1.57M | -866.81K | -735.3K | -145.25K | -1.40M | -451.40K | -165.16K | -394.92K | -711 |
Financing activities | ||||||||||
Common Stock Issued | 240K | 14.12M | 24.19M | 25.74M | 25.69M | 13.50M | 13.77M | 0 | 17.39M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.11K |
Repayments of term debt | 0 | -1.15M | -702.58K | 0 | -1.35M | 0 | -1.23M | 0 | -2.36M | 0 |
Cash used in financing activities | -1.87M | 12.37M | 25.72M | 29.66M | 23.77M | 18.58M | 11.93M | 18.77M | 20.29M | 6.08M |
Net Change In Cash | -15.96M | 14.49M | 5.06M | 5.87M | 1.27M | -2.46M | -4.21M | 3.45M | 5.29M | -116.07K |
Cash at end of period | 12.89M | 28.86M | 14.36M | 9.30M | 3.42M | 2.14M | 4.60M | 8.82M | 5.36M | 69.17K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |